don't worry, page-34

As an accountant I would analyse Kynamro as being in deep trouble. This is not a blockbuster drug, the competitions sales were declared as being only $48M whereas Genzyme has refused to advise on its sales. As an additional effort to increase sales Genzyme has put a greater sales force into place in order to try to salvage the situation.

As I have often stated ISIS. with only two products to have ever reached market, desperately need additional products to reach market. With the possibility of Genzyme deciding to discontinue marketing Kynamro after the current effort to shore up this product, ISIS will be left once again without a product in the market place. In my opinion ANP has three such products Acromegaly, Stem Cell Mobilisation and MS.